Fem1b Inhibitors
Tech ID: 32345 / UC Case 2021-139-0
Patent Status
| Country | Type | Number | Dated | Case |
| United States Of America | Published Application | 20240287006 | 08/29/2024 | 2021-139 |
| Japan | Published Application | 2024-525158 | 07/10/2024 | 2021-139 |
| European Patent Office | Published Application | 4355327 | 04/24/2024 | 2021-139 |
| Mexico | Published Application | TO COME | 04/11/2024 | 2021-139 |
| China | Published Application | 117794533 | 03/29/2024 | 2021-139 |
| Australia | Published Application | WO 2022/266321 | 12/22/2022 | 2021-139 |
| Brazil | Published Application | WO 2022/266321 | 12/22/2022 | 2021-139 |
| Canada | Published Application | WO 2022/266321 | 12/22/2022 | 2021-139 |
| Israel | Published Application | WO 2022/266321 | 12/22/2022 | 2021-139 |
| India | Published Application | WO 2022/266321 | 12/22/2022 | 2021-139 |
| Rep Of Korea | Published Application | WO 2022/266321 | 12/22/2022 | 2021-139 |
| Russian Federation | Published Application | WO 2022/266321 | 12/22/2022 | 2021-139 |
Brief Description
UC Berkeley researchers have discovered novel, specific Fem1b inhibitors. Fem1b is essential in lymphoma and lung cancer cells. Fem1b inhibition could be beneficial in cancer, metabolic disease, obesity, diabetes and other diseases.
Suggested uses
- therapeutics
Contact
- Craig K. Kennedy
- craig.kennedy@berkeley.edu
- tel: View Phone Number.
Inventors
- Rape, Michael
